Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons.

Anti-cancer drugs - 1 Nov 2023

Jiang Fengxian, Lai Jingjiang, Zhuo Xiaoli, Liu Lei, Yang Yucheng, Zhang Junlei, Zhao Jing, Xu Wei, Wang Jingliang, Wang Cuiyan, Fu Guobin

Abstract excerpt

Approximately 15-20% of the patients with breast cancer overexpress human epidermal growth factor receptor 2 ( HER2 ). HER2 -positive breast cancer is highly aggressive and has a high relapse rate, suggesting that it is prone to and progresses rapidly after drug resistance. Pyrotinib resistance and changes in patients' conditions after drug resistance are challenging clinical issues and require medical attention....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Gene Fusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Mutation

Share to Proto-Oncogene Proteins c-ret

Share to Receptor, ErbB-2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 36689646
DOI: 10.1097/CAD.0000000000001506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons.PMID 36689646Read ↗

<p>Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report</p>Semantic proximity Read ↗

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Semantic proximity Read ↗

The efficacy and safety of pyrotinib in treating HER2-positive metastatic breast cancer patients:A multi-center studySemantic proximity Read ↗

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.Semantic proximity Read ↗

PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report.Semantic proximity Read ↗

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerSemantic proximity Read ↗

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.Semantic proximity Read ↗

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.Semantic proximity Read ↗

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.Semantic proximity Read ↗

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

Analysis of different HER-2 mutations in breast cancer progression and drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.